New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
08:21 EDTMYLMylan price target raised to $63 from $50 at Goldman
Goldman raised Mylan's price target to $63 from $50 following the Q1 beat and favorable guidance. Shares are Buy rated.
News For MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
09:35 EDTMYLMylan potential acquisition of Perrigo looks questionable says Bernstein
Subscribe for More Information
October 5, 2015
10:02 EDTMYLBofa/Merrill healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
September 30, 2015
14:58 EDTMYLMylan volatility at 52-week high
Mylan October weekly put option implied volatility is at 70, October is at 57, November is at 54; compared to its 52-week range of 26 to 58, suggesting large price movement.
11:06 EDTMYLStocks with call strike movement; FSLR MYL
First Solar (FSLR) January 50 call option implied volatility decreased 5% to 47, Mylan (MYL) January 47 call option implied volatility increased 4% to 48 according to IVolatility.
September 29, 2015
12:35 EDTMYLPerrigo shareholders pressure company to explore sale, Reuters says
Certain Perrigo (PRGO) shareholders have requested that company explore a sale, hoping for an alternative to Mylan's (MYL) approximately $25B hostile bid, Reuters reports, citing people familiar with the matter. The pressure represents a challenge to Perrigo's defense strategy, the report says. Some of the company's shareholders view Novartis (NVS), Sanofi (SNY), Procter & Gamble (PG), and Colgate-Palmolive (CL) as potential suitors, the report says. Reference Link
September 28, 2015
07:31 EDTMYLMylan launches generic Invega tablets
Subscribe for More Information
07:27 EDTMYLFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
September 25, 2015
13:51 EDTMYLBMO's pharma predictions for rest of year include take on Mylan, Perrigo
BMO Capital analyst David Maris rolled out his rest of year predictions for the Specialty Pharmaceuticals space. Among them is his belief that Mylan (MYL) will be unsuccessful in acquiring Perrigo (PRGO). Perrigo will either be acquired by another company or make an acquisition itself, Maris tells investors in a research note. His other predictions include Jazz Pharmaceuticals (JAZZ) proving to be a good buying opportunity amidst the current negative sentiment and ZS Pharma (ZSPH) offering upside following the recent pullback given the potential for a near-term buyout and prospects for its "best in class drug for hyperkalemia" winning approval in 2016.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use